SCHEDULE 13G: EcoR1 Capital and Oleg Nodelman Disclose 6.9% Passive Stake in iTeos Therapeutics

EcoR1 Capital, LLC and its control person Oleg Nodelman have reported a passive beneficial ownership of 6.9% in iTeos Therapeutics, Inc. common stock as of May 1, 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed a Schedule 13G indicating beneficial ownership in iTeos Therapeutics, Inc.
• EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 2,656,640 shares of iTeos Therapeutics common stock, representing 6.9% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 2,490,694 shares, representing 6.5% of the class.
• The percentage of class is calculated based on 38,273,795 shares of Common Stock outstanding on April 22, 2025, as reported in the Issuer's Form 10-Q for the quarter ended March 31, 2025.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of iTeos Therapeutics, Inc.
• EcoR1 Capital, LLC acts as the general partner and investment adviser for funds including EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman is the control person of EcoR1 Capital, LLC.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable investment firm like EcoR1 Capital can be viewed positively by the market, suggesting confidence in the company's value or future prospects. While it's a passive stake, it still represents a vote of confidence.

Positives

• A significant institutional investor, EcoR1 Capital, has taken a substantial passive stake in iTeos Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The filing indicates a passive investment, suggesting the investor is not seeking to influence control, which can be viewed positively by current management.

Future Outlook

The document does not provide forward-looking statements or guidance from iTeos Therapeutics, as it is a beneficial ownership filing by an external investor.

Management Comments

• The document contains certifications from Oleg Nodelman stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The filing indicates a significant investment by a specialized healthcare/biotechnology investor (EcoR1 Capital) in iTeos Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such investments are common in the industry as institutional funds seek to capitalize on growth opportunities in innovative drug development or therapeutic areas.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for investors acquiring more than 5% of a company's shares with a passive intent.
• EcoR1 Capital's investment strategy often focuses on healthcare and biotechnology companies, aligning with typical institutional investment patterns in this sector.
• No specific comparable companies or projects are mentioned in the filing itself.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively.

Key Dates

Recommendation

Keywords

iTeos Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Healthcare Investment